Johnson & Johnson Vision Highlights Latest Innovations at ESCRS 2017 Meeting in Lisbon, Portugal

highlighted in scientific presentations underscore company’s commitment to improving and restoring sight for patients worldwide 

SANTA ANA, Calif. (October 5, 2017) – Johnson & Johnson Vision will showcase its latest innovations in Surgical Vision at the XXXV Congress of the ESCRS, including the introduction of the new iDESIGN® Refractive Studio, as well as a first-look at the CATALYS® System Mobile Patient Bed. In addition to activities at the Johnson & Johnson Vision booth (P1127), attendees have the opportunity to learn more via a broad range of presentations and poster sessions. 

“We are showcasing patient-centric innovation with the launch of the iDESIGN® Refractive Studio, CATALYS® System Mobile Patient Bed, and our newest dry eye medical device technologies through our acquisition of TearScience,” said Tom Frinzi, Worldwide President, Surgical, Johnson & Johnson Vision. “All of these uniquely address unmet patient needs through innovations in customization and patient comfort.” 

Johnson & Johnson Vision began its journey more than 30 years ago when it first entered the eye health market and grew through its world-leading ACUVUE® Brand Contact Lens portfolio. The acquisition of Abbott Medical Optics in 2017 added strong and differentiated surgical ophthalmic technologies to the company’s portfolio. The latest acquisition of TearScience further strengthens the Johnson & Johnson Vision portfolio, adding technologies that address Meibomian Gland Dysfunction – the leading underlying cause of Dry Eye Disease. 

Johnson & Johnson Vision is presenting at ESCRS through its surgical vision operating company, Abbott Medical Optics Inc. 



iDESIGN® Refractive Studio 
Johnson & Johnson Vision introduces the new iDESIGN® Refractive Studio which enhances the current wavefront-guided treatment with corneal topography measurements to deliver the next level of customized treatment to further drive high patient satisfaction and provide quality visual outcomes. 

Johnson & Johnson Vision launches the CATALYS® Precision Laser System Mobile Patient Bed. 

The Mobile Patient Bed is the latest innovation for the CATALYS® System, and it is designed to optimize workflow from cataract patient preparation through postsurgical recovery. The bed integrates seamlessly with the CATALYS® System through Bluetooth connectivity and the ergonomic design includes a headrest designed to stabilize the patient’s head for cataract surgery. The ability to adapt the bed to multiple positions and back conditions helps ensure premium comfort for patients. 

In September, Johnson & Johnson Vision completed its acquisition of TearScience, Inc., expanding the company’s eye health portfolio and its presence in the growing Dry Eye Disease (DED) treatment market. TearScience is a medical device manufacturer of products dedicated to evaluating meibomian gland health and treating meibomian gland dysfunction (MGD), the leading cause of DED.(1) 

It is well recognized that DED is a significant unmet need, affecting an estimated 340 million patients worldwide – and MGD is the leading cause. Johnson & Johnson Vision seeks to accelerate the development and expansion of these medical device technologies to reach more eye health providers and patients. 



Edward Manche, MD
A prospective, randomized, contralateral, eye-to-eye comparison of wavefront-guided (WFG) LASIK to SMILE surgery in myopic patients 

  • E-Poster: Terminals are located in the Poster Village on Level 1 
  • Late-breaking data will reveal how the gold standard procedure of WFG LASIK compared to SMILE in clinical outcomes. 

Surendra Basti, MD
Prospective randomized evaluation of intraocular lens centration with scanned capsule vs. limbus-based capsulotomy for femtosecond laser-assisted cataract surgery 

  • Paper Session: Sunday, October 8, 8:30 AM - Room 3.6 
  • Results to show how scanned capsule capsulotomies (a capability unique to the CATALYS® system) compares to limbus-based capsulotomies over the course of one year. 

Kjell Gunnar Gundersen, MD 
Visual performance and quality of vision with a toric extended-range-of-vision intraocular lens 

  • Poster Session: Sunday, October 8, 2:24 PM - Poster Village Pod 1
  • An independent study evaluating patient satisfaction, position stability and UCVA across distances for the Tecnis Symfony toric EDOF IOL. 

1.Nichols_The international workshop Meibomian Gland Dysfunction_Invest Ophthalmol Vis Scie_2011_52_4 (v0.1) p. 1. 


Johnson & Johnson Vision 
Johnson & Johnson Vision, through its operating companies, is committed to improving and restoring sight for patients worldwide. Since debuting the world’s first disposable soft contact lens in 1987, Johnson & Johnson Vision Care, Inc. has been helping patients see better through their world-leading ACUVUE® Brand Contact Lenses portfolio. In 2017, with the addition of Abbott Medical Optics Inc., the Johnson & Johnson Surgical Vision business, Johnson & Johnson invested further in eye health by expanding into cataract surgery, laser refractive surgery (LASIK) and consumer eye health. Serving more than 60 million patients across 103 countries, Johnson & Johnson Vision is committed to helping more people in more places improve or restore their sight. Dual headquartered in Jacksonville, Florida, and Santa Ana, California, Johnson & Johnson Vision has more than 10,000 employees worldwide. 

Media Contact: 
Kim Montagnino
(631) 375-8779 


© 2017 Abbott Medical Optics Inc. iDESIGN and CATALYS are trademarks owned by or licensed to Abbott Medical Optics Inc., its subsidiaries or affiliates. All other trademarks are the intellectual property of their respective owners. PP2017OTH0748